Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma - PubMed (original) (raw)
Clinical Trial
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma
B Fisher et al. J Clin Oncol. 1989 Feb.
Abstract
Lymphoid cells infiltrating into human tumors can be expanded in vitro in medium containing interleukin-2 (IL-2). Adoptive transfer of these tumor-infiltrating lymphocytes (TIL) mediates potent antitumor effects in murine tumor models. Clinical trials to evaluate the efficacy of these cells in patients with advanced cancer are underway. We have investigated whether infused TIL labeled with indium 111 (111In) oxine can traffic and localize to metastatic deposits of tumor. Six patients with metastatic malignant melanoma who had multiple sites of subcutaneous, nodal, and/or visceral disease were the subjects of the study. The patients received cyclophosphamide 36 hours before receiving the intravenous (IV) infusion of TIL followed by IL-2 IV every eight hours. The distribution and localization of the TIL were evaluated using serial whole body gamma camera imaging, serial blood and urine samplings, and serial biopsies of tumor and normal tissue. 111In-labeled TIL localized to lung, liver, and spleen within two hours after the infusion of activity. Activity in the lung diminished within 24 hours. As early as 24 hours after injection of 111In-labeled TIL, localization of TIL to sites of metastatic deposits was demonstrated in all six patients using either imaging studies or biopsy specimens or both. 111In activity in tumor tissue biopsies ranged from three to 40 times greater than activity in normal tissue. A progressive increase in the radioactive counts at sites of tumor deposit was seen. This study shows that labeled TIL can localize preferentially to tumor, and provides information concerning the possible mechanism of the therapeutic effects of TIL.
Similar articles
- In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma.
Griffith KD, Read EJ, Carrasquillo JA, Carter CS, Yang JC, Fisher B, Aebersold P, Packard BS, Yu MY, Rosenberg SA. Griffith KD, et al. J Natl Cancer Inst. 1989 Nov 15;81(22):1709-17. doi: 10.1093/jnci/81.22.1709. J Natl Cancer Inst. 1989. PMID: 2810387 - Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, Carasquillo JA, Steinberg SM, Rosenberg SA, Yang JC. Pockaj BA, et al. Cancer. 1994 Mar 15;73(6):1731-7. doi: 10.1002/1097-0142(19940315)73:6<1731::aid-cncr2820730630>3.0.co;2-h. Cancer. 1994. PMID: 8156501 Clinical Trial. - Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer.
Dillman RO, Hurwitz SR, Schiltz PM, Barth NM, Beutel LD, Nayak SK, O'Connor AA. Dillman RO, et al. Cancer Biother Radiopharm. 1997 Apr;12(2):65-71. doi: 10.1089/cbr.1997.12.65. Cancer Biother Radiopharm. 1997. PMID: 10851449 - White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C; Immunotherapy Task Force of the NCI Investigational Drug Steering Committee. Weber J, et al. Clin Cancer Res. 2011 Apr 1;17(7):1664-73. doi: 10.1158/1078-0432.CCR-10-2272. Epub 2011 Feb 15. Clin Cancer Res. 2011. PMID: 21325070 Review. - Prospects for gene therapy and lymphokine therapy for metastatic melanoma.
Sivanandham M, Scoggin SD, Sperry RG, Wallack MK. Sivanandham M, et al. Ann Plast Surg. 1992 Jan;28(1):114-8. doi: 10.1097/00000637-199201000-00029. Ann Plast Surg. 1992. PMID: 1642399 Review.
Cited by
- In Vivo Cellular Magnetic Imaging: Labeled vs. Unlabeled Cells.
Bulte JWM, Wang C, Shakeri-Zadeh A. Bulte JWM, et al. Adv Funct Mater. 2022 Dec 9;32(50):2207626. doi: 10.1002/adfm.202207626. Epub 2022 Aug 22. Adv Funct Mater. 2022. PMID: 36589903 Free PMC article. - Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.
Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL Jr. Engelhard VH, et al. J Immunol. 2018 Jan 15;200(2):432-442. doi: 10.4049/jimmunol.1701269. J Immunol. 2018. PMID: 29311385 Free PMC article. Review. - Imaging of T-cell Responses in the Context of Cancer Immunotherapy.
Xiao Z, Puré E. Xiao Z, et al. Cancer Immunol Res. 2021 May;9(5):490-502. doi: 10.1158/2326-6066.CIR-20-0678. Cancer Immunol Res. 2021. PMID: 33941536 Free PMC article. Review. - Human autologous tumor-specific T cells in malignant melanoma.
Platsoucas CD. Platsoucas CD. Cancer Metastasis Rev. 1991 Jun;10(2):151-76. doi: 10.1007/BF00049412. Cancer Metastasis Rev. 1991. PMID: 1873855 Review. - Injectable Biomimetic Hydrogels as Tools for Efficient T Cell Expansion and Delivery.
Weiden J, Voerman D, Dölen Y, Das RK, van Duffelen A, Hammink R, Eggermont LJ, Rowan AE, Tel J, Figdor CG. Weiden J, et al. Front Immunol. 2018 Nov 28;9:2798. doi: 10.3389/fimmu.2018.02798. eCollection 2018. Front Immunol. 2018. PMID: 30546367 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials